NCT07146711View on ClinicalTrials.gov

A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

October 1, 2025

Study Completion Date

December 1, 2025

Conditions

Healthy Adult Males Volunteers

Interventions

DRUG

Tamsulosin (0.4 mg/j)

Multiple dose administration (7 days)

DRUG

Omnic Ocas®,

Multiple dose administration (7 days)

Trial Locations (1)

0037

"Tonus-Les LLC", Yerevan

All Listed Sponsors

lead

Berlin-Chemie AG Menarini Group

INDUSTRY

NCT07146711 - A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State | Biotech Hunter | Biotech Hunter